RxDoctor Payments Data

Edward Nelson, MD

Hematology & Oncology · Orange, CANPI 1780764951

Payments from drug & device makers

What this record shows

That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$141,962in research payments, 2019–2025

Across 8 payments — averaging $17,745 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$104K
  • Genentech, Inc.$22K
  • TG Therapeutics, Inc.$16K

How this compares

$0 in reported general payments places this provider in the 0th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024
$15,426
Medicare patients
71
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib34$685,935
CalquenceAcalabrutinib Maleate12$178,374
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$26,306
Potassium Chloride15$178
Allopurinol11$62

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Orange

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →